Table 2 Recent studies concerning SLR
From: Salvage thoracic surgery in patients with lung cancer: potential indications and benefits
Authors | Years | N | Indication | Timing of surgery in weeks (range) | Mortality (%) | Morbidity (%) | Follow-up (months) | Overall survival (months) | Relapse-free survival (months) |
|---|---|---|---|---|---|---|---|---|---|
Uramoto et al. [12] | 2014 | 8 | Mixed | n.g | 0 | 25 | 14 | n.g. | 5.9 |
Yang et al. [7] | 2015 | 31 | Recurrent or persistent tumor after radiotherapy | 18 (8–111) | 0l | 48 | n.g. | 32 | 10 |
Dickhoff et al. [14] | 2016 | 15 | Local recurrence and persistent tumor after chemo-, radiotherapy | 21 (3–95) | 6.7 | 40 | 12.1 | 46 | 43.6 |
Schreiner et al. [3] | 2016 | 9 | Local recurrence after chemo-, radiotherapy | 30 (12–165) | 11 | 22 | 30 | 23 | 21 |
Verstegen et al. [17] | 2016 | 9 | Recurrent or persistent tumor after stereotactic radiotherapy | n.g. | 0 | 33 | 19 | 26 | n.g. |
Shimada et al. [15] | 2016 | 18 | Local recurrence and persistent tumor after chemo-, radiotherapy | 38 (3–282) | 0 | 28 | 47 | n.g. | n.g. |
Mizobuchi et al. [18] | 2016 | 12 | Recurrent or persistent tumor after radiotherapy | 96 (36–312) | 0 | n.s. | 18 | n.g. | n.g. |
Sawada et al. [16] | 2017 | 8 | Local recurrence and persistent tumor after chemo-, radiotherapy | n.g. | 0 | 38 | 48 | n.g. | n.g |
This study | 2017 | 30 | Mixed | n.g. | 3 | 70 | 15 | 15 | 11 |
Only GI patients | 22 | Recurrent or persistent tumor after definitive chemo-, radiotherapy, or previous surgery and ajduvant treatment | 24 | 0 | 64 | 22 | 22 | 16 |